149 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … established for such purpose for services rendered to the Company, provided that any securities issued to consultants pursuant to this clause (a) shall
8-K
EX-4.2
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation … for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
8-K
EX-4.1
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental … prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
8-K
EX-99.1
kzrwi6 yj42h3b
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
8-K
EX-99.1
8u5myb8akjfba
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
8-K
EX-4.2
0echghsa
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-10.1
oj9ucl pwfxr076
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.1
thgwdw
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.3
1he cwwz2
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
424B5
89y4c9d7wktln3
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-1.1
gc2v0mke
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
424B5
7ym 8qzeaw
21 Jul 23
Prospectus supplement for primary offering
4:39pm
S-8
sfreom2o cax7
14 Jul 23
Registration of securities for employees
5:12pm